As previously reported, Cantor Fitzgerald raised the firm’s price target on Harrow (HROW) to $94 from $76 and keeps an Overweight rating on the shares following quarterly results. The firm now models $29M Vevye revenues in Q4, which would mean FY25 Vevye revenue would fall short of over $100M target/guidance by $8M — not a huge deal, Cantor says, but increases pressure on 2026 where new insurance coverage and continued market share growth need to be matched by proportional revenue growth.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow price target raised to $94 from $76 at Cantor Fitzgerald
- Harrow Health: Strong Product Performance and Strategic Moves Justify Buy Rating
- Closing Bell Movers: CoreWeave down over 5% on lower sales, higher capex view
- Harrow Health Reports Strong Q3 2025 Financial Results
- Harrow reports Q3 core EPS 33c, consensus 29c